SEC Tracker
Get the app

Nutra Pharma NPHC

Nutra Pharma Q2 FY26: revenue $34K, down 59%; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Nutra Pharma reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$34K−59% from $85K in Q2 FY2510-Q income statement, on EDGAR
  2. Net income−$3.9M−1168% from $370K in Q2 FY2510-Q income statement, on EDGAR
  3. Diluted EPS$0.00Against $0.00 in Q2 FY2510-Q income statement, on EDGAR
  4. Cash from operations−$251KAgainst −$288K in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Nutra Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. International Stem Cell ISCO public float $592K, Jun 30, 2025
  2. Emmaus Life Sciences EMMA public float $582K, Jun 30, 2025
  3. Mosaic ImmunoEngineering CPMV public float $856K, Jun 30, 2025
  4. Avenue Therapeutics ATXI public float $572K, Jun 30, 2025
  5. China Foods Holdings CFOO public float $864K, Jun 30, 2025